Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 439 entries
Sorted by: Best Match Show Resources per page
Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women.

Case reports in women's health

De Ycaza AE, Chang AY, Jensen JR, Khan Z, Erickson D.
PMID: 27668187
Case Rep Womens Health. 2015 Oct;8:9-12. doi: 10.1016/j.crwh.2015.09.001. Epub 2015 Sep 24.

OBJECTIVE: To describe 2 cases of macroprolactinomas with atypical presentation in women desiring pregnancy that illustrate important considerations in the management approach for macroprolactinomas in reproductive-aged women.PATIENTS: Case 1 was a 26-year-old woman referred to our institution for possible...

Cite
De Ycaza AE, Chang AY, Jensen JR, et al. Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women. Case Rep Womens Health. 2015;8:9-12doi: 10.1016/j.crwh.2015.09.001.
De Ycaza, A. E., Chang, A. Y., Jensen, J. R., Khan, Z., & Erickson, D. (2015). Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women. Case reports in women's health, 89-12. https://doi.org/10.1016/j.crwh.2015.09.001
De Ycaza, Ana Espinosa, et al. "Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women." Case reports in women's health vol. 8 (2015): 9-12. doi: https://doi.org/10.1016/j.crwh.2015.09.001
De Ycaza AE, Chang AY, Jensen JR, Khan Z, Erickson D. Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women. Case Rep Womens Health. 2015 Oct;8:9-12. doi: 10.1016/j.crwh.2015.09.001. Epub 2015 Sep 24. PMID: 27668187; PMCID: PMC5033506.
Copy Download .nbib Format: NLM
Treatment of sleep-related eating disorder.

Current treatment options in neurology

Chiaro G, Caletti MT, Provini F.
PMID: 26037737
Curr Treat Options Neurol. 2015 Aug;17(8):361. doi: 10.1007/s11940-015-0361-6.

OPINION STATEMENT: Sleep-related eating disorder (SRED) is classified as an NREM-related parasomnia characterized by recurrent episodes of dysfunctional eating that occur after an arousal from the main sleep period with partial or complete amnesia for the event, resulting in...

Cite
Chiaro G, Caletti MT, Provini F. Treatment of sleep-related eating disorder. Curr Treat Options Neurol. 2015;17(8):361doi: 10.1007/s11940-015-0361-6.
Chiaro, G., Caletti, M. T., & Provini, F. (2015). Treatment of sleep-related eating disorder. Current treatment options in neurology, 17(8), 361. https://doi.org/10.1007/s11940-015-0361-6
Chiaro, Giacomo, et al. "Treatment of sleep-related eating disorder." Current treatment options in neurology vol. 17,8 (2015): 361. doi: https://doi.org/10.1007/s11940-015-0361-6
Chiaro G, Caletti MT, Provini F. Treatment of sleep-related eating disorder. Curr Treat Options Neurol. 2015 Aug;17(8):361. doi: 10.1007/s11940-015-0361-6. PMID: 26037737.
Copy Download .nbib Format: NLM
Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review.

Cureus

Moisi M, Cruz AS, Benkers T, Rostad S, Broyles FB, Yuen K, Mayberg M.
PMID: 27489751
Cureus. 2016 Jun 27;8(6):e658. doi: 10.7759/cureus.658.

Most prolactin-secreting pituitary adenomas demonstrate slow growth and are effectively managed with medical/surgical therapy. Rarely, these tumors can behave aggressively with rapid growth and invasion of local tissues, and are refractory to medical, surgical, or radio-surgical therapies. We report...

Cite
Moisi M, Cruz AS, Benkers T, et al. Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review. Cureus. 2016;8(6):e658doi: 10.7759/cureus.658.
Moisi, M., Cruz, A. S., Benkers, T., Rostad, S., Broyles, F. B., Yuen, K., & Mayberg, M. (2016). Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review. Cureus, 8(6), e658. https://doi.org/10.7759/cureus.658
Moisi, Marc, et al. "Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review." Cureus vol. 8,6 (2016): e658. doi: https://doi.org/10.7759/cureus.658
Moisi M, Cruz AS, Benkers T, Rostad S, Broyles FB, Yuen K, Mayberg M. Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A Review. Cureus. 2016 Jun 27;8(6):e658. doi: 10.7759/cureus.658. PMID: 27489751; PMCID: PMC4963231.
Copy Download .nbib Format: NLM
Dopamine and the biology of creativity: lessons from Parkinson's disease.

Frontiers in neurology

Lhommée E, Batir A, Quesada JL, Ardouin C, Fraix V, Seigneuret E, Chabardès S, Benabid AL, Pollak P, Krack P.
PMID: 24795692
Front Neurol. 2014 Apr 22;5:55. doi: 10.3389/fneur.2014.00055. eCollection 2014.

BACKGROUND: Parkinson's disease (PD) is characterized by reduced flexibility, conceptualization, and visuo-spatial abilities. Although these are essential to creativity, case studies show emergence of creativity during PD. Knowledge about the role of dopamine in creativity so far only stems...

Cite
Lhommée E, Batir A, Quesada JL, et al. Dopamine and the biology of creativity: lessons from Parkinson's disease. Front Neurol. 2014;5:55doi: 10.3389/fneur.2014.00055.
Lhommée, E., Batir, A., Quesada, J. L., Ardouin, C., Fraix, V., Seigneuret, E., Chabardès, S., Benabid, A. L., Pollak, P., & Krack, P. (2014). Dopamine and the biology of creativity: lessons from Parkinson's disease. Frontiers in neurology, 555. https://doi.org/10.3389/fneur.2014.00055
Lhommée, Eugénie, et al. "Dopamine and the biology of creativity: lessons from Parkinson's disease." Frontiers in neurology vol. 5 (2014): 55. doi: https://doi.org/10.3389/fneur.2014.00055
Lhommée E, Batir A, Quesada JL, Ardouin C, Fraix V, Seigneuret E, Chabardès S, Benabid AL, Pollak P, Krack P. Dopamine and the biology of creativity: lessons from Parkinson's disease. Front Neurol. 2014 Apr 22;5:55. doi: 10.3389/fneur.2014.00055. eCollection 2014. PMID: 24795692; PMCID: PMC4001035.
Copy Download .nbib Format: NLM
Diffuse Lewy Body Disease.

Current treatment options in neurology

Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA.
PMID: 11581527
Curr Treat Options Neurol. 2001 Nov;3(6):507-518. doi: 10.1007/s11940-001-0013-x.

Diffuse Lewy body disease (DLB) is a neurodegenerative disorder characterized by dementia, fluctuations in mental status, hallucinations, and parkinsonism. Diffuse Lewy body disease is the second most common cause of dementia, following Alzheimer's disease. The treatment of DLB includes...

Cite
Zesiewicz TA, Baker MJ, Dunne PB, et al. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001;3(6):507-518doi: 10.1007/s11940-001-0013-x.
Zesiewicz, T. A., Baker, M. J., Dunne, P. B., & Hauser, R. A. (2001). Diffuse Lewy Body Disease. Current treatment options in neurology, 3(6), 507-518. https://doi.org/10.1007/s11940-001-0013-x
Zesiewicz, Theresa A., et al. "Diffuse Lewy Body Disease." Current treatment options in neurology vol. 3,6 (2001): 507-518. doi: https://doi.org/10.1007/s11940-001-0013-x
Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001 Nov;3(6):507-518. doi: 10.1007/s11940-001-0013-x. PMID: 11581527.
Copy Download .nbib Format: NLM
Dopamine agonists: the treatment for Parkinson's disease in the XXI century?.

Parkinsonism & related disorders

Lledó A.
PMID: 11008196
Parkinsonism Relat Disord. 2000 Nov 01;7(1):51-58. doi: 10.1016/s1353-8020(00)00038-9.

Levodopa combined with a peripheral dopa-decarboxylase inhibitor (DCI) has been considered the therapy of choice for Parkinson's disease (PD). Levodopa is nearly always effective, but has a high incidence of adverse effects with long term use, including response fluctuations...

Cite
Lledó A. Dopamine agonists: the treatment for Parkinson's disease in the XXI century?. Parkinsonism Relat Disord. 2000;7(1):51-58doi: 10.1016/s1353-8020(00)00038-9.
Lledó, A. (2000). Dopamine agonists: the treatment for Parkinson's disease in the XXI century?. Parkinsonism & related disorders, 7(1), 51-58. https://doi.org/10.1016/s1353-8020(00)00038-9
Lledó. "Dopamine agonists: the treatment for Parkinson's disease in the XXI century?." Parkinsonism & related disorders vol. 7,1 (2000): 51-58. doi: https://doi.org/10.1016/s1353-8020(00)00038-9
Lledó A. Dopamine agonists: the treatment for Parkinson's disease in the XXI century?. Parkinsonism Relat Disord. 2000 Nov 01;7(1):51-58. doi: 10.1016/s1353-8020(00)00038-9. PMID: 11008196.
Copy Download .nbib Format: NLM
Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study.

Parkinsonism & related disorders

Caraceni T, Musicco M.
PMID: 11248591
Parkinsonism Relat Disord. 2001 Apr;7(2):107-114. doi: 10.1016/s1353-8020(00)00023-7.

Objectives: levodopa improves the quality of life in parkinsonian patients, however long term response is compromised by the emergence of motor fluctuations and dyskinesias. The aim of this study was to compare the occurrence of motor fluctuations and dyskinesias...

Cite
Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. Parkinsonism Relat Disord. 2001;7(2):107-114doi: 10.1016/s1353-8020(00)00023-7.
Caraceni, T., & Musicco, M. (2001). Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. Parkinsonism & related disorders, 7(2), 107-114. https://doi.org/10.1016/s1353-8020(00)00023-7
Caraceni, T, and Musicco, M. "Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study." Parkinsonism & related disorders vol. 7,2 (2001): 107-114. doi: https://doi.org/10.1016/s1353-8020(00)00023-7
Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. Parkinsonism Relat Disord. 2001 Apr;7(2):107-114. doi: 10.1016/s1353-8020(00)00023-7. PMID: 11248591.
Copy Download .nbib Format: NLM
Restless Legs Syndrome.

Current treatment options in neurology

Lesage S, Earley CJ.
PMID: 15043804
Curr Treat Options Neurol. 2004 May;6(3):209-219. doi: 10.1007/s11940-004-0013-8.

In the past 10 years, restless legs syndrome (RLS) has gained recognition as a common sleep disorder. There are several therapeutic options in treating patients with RLS. RLS causes significant sleep disturbance and negatively impacts on patient quality of...

Cite
Lesage S, Earley CJ. Restless Legs Syndrome. Curr Treat Options Neurol. 2004;6(3):209-219doi: 10.1007/s11940-004-0013-8.
Lesage, S., & Earley, C. J. (2004). Restless Legs Syndrome. Current treatment options in neurology, 6(3), 209-219. https://doi.org/10.1007/s11940-004-0013-8
Lesage, Suzanne, and Earley, Christopher J.. "Restless Legs Syndrome." Current treatment options in neurology vol. 6,3 (2004): 209-219. doi: https://doi.org/10.1007/s11940-004-0013-8
Lesage S, Earley CJ. Restless Legs Syndrome. Curr Treat Options Neurol. 2004 May;6(3):209-219. doi: 10.1007/s11940-004-0013-8. PMID: 15043804.
Copy Download .nbib Format: NLM
Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey.

Behavioural pharmacology

Katz JL, Alling K, Shores E, Witkin JM.
PMID: 11224321
Behav Pharmacol. 1995 Mar;6(2):143-148.

Behavioral effects of several dopamine D1 receptor agonists were compared with those of cocaine and (+)-amphetamine in squirrel monkeys trained to press a response key under a fixed-interval schedule of electric shock presentation. Cocaine (0.03 to 0.3mg/kg) and (+)-amphetamine...

Cite
Katz JL, Alling K, Shores E, et al. Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behav Pharmacol. 1995;6(2):143-148
Katz, J. L., Alling, K., Shores, E., & Witkin, J. M. (1995). Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behavioural pharmacology, 6(2), 143-148.
Katz, J.L., et al. "Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey." Behavioural pharmacology vol. 6,2 (1995): 143-148.
Katz JL, Alling K, Shores E, Witkin JM. Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behav Pharmacol. 1995 Mar;6(2):143-148. PMID: 11224321.
Copy Download .nbib Format: NLM
Dopamine agonists and the risk of valvular heart disease.

Nature clinical practice. Neurology

Martin WR.
PMID: 17563771
Nat Clin Pract Neurol. 2007 Aug;3(8):426-7. doi: 10.1038/ncpneuro0534. Epub 2007 Jun 12.

No abstract available.

Cite
Martin WR. Dopamine agonists and the risk of valvular heart disease. Nat Clin Pract Neurol. 2007;3(8):426-7doi: 10.1038/ncpneuro0534.
Martin, W. R. (2007). Dopamine agonists and the risk of valvular heart disease. Nature clinical practice. Neurology, 3(8), 426-7. https://doi.org/10.1038/ncpneuro0534
Martin, W R Wayne. "Dopamine agonists and the risk of valvular heart disease." Nature clinical practice. Neurology vol. 3,8 (2007): 426-7. doi: https://doi.org/10.1038/ncpneuro0534
Martin WR. Dopamine agonists and the risk of valvular heart disease. Nat Clin Pract Neurol. 2007 Aug;3(8):426-7. doi: 10.1038/ncpneuro0534. Epub 2007 Jun 12. PMID: 17563771.
Copy Download .nbib Format: NLM
Restless leg syndrome: is it a real problem?.

Therapeutics and clinical risk management

Cotter PE, O'Keeffe ST.
PMID: 18360657
Ther Clin Risk Manag. 2006 Dec;2(4):465-75. doi: 10.2147/tcrm.2006.2.4.465.

Restless legs syndrome (RLS) is a common condition that is frequently unrecognized, misdiagnosed and poorly managed. It is characterized by uncomfortable sensations deep in the legs developing at rest that compel the person to move; symptoms are worst at...

Cite
Cotter PE, O'Keeffe ST. Restless leg syndrome: is it a real problem?. Ther Clin Risk Manag. 2006;2(4):465-75doi: 10.2147/tcrm.2006.2.4.465.
Cotter, P. E., & O'Keeffe, S. T. (2006). Restless leg syndrome: is it a real problem?. Therapeutics and clinical risk management, 2(4), 465-75. https://doi.org/10.2147/tcrm.2006.2.4.465
Cotter, Paul E, and O'Keeffe, Shaun T. "Restless leg syndrome: is it a real problem?." Therapeutics and clinical risk management vol. 2,4 (2006): 465-75. doi: https://doi.org/10.2147/tcrm.2006.2.4.465
Cotter PE, O'Keeffe ST. Restless leg syndrome: is it a real problem?. Ther Clin Risk Manag. 2006 Dec;2(4):465-75. doi: 10.2147/tcrm.2006.2.4.465. PMID: 18360657; PMCID: PMC1936366.
Copy Download .nbib Format: NLM
The role of pramipexole in a severe Parkinson's disease model in mice.

Therapeutic advances in neurological disorders

Elhak SG, Ghanem AA, Abdelghaffar H, Eldakroury S, Eltantawy D, Eldosouky S, Salama M.
PMID: 21179594
Ther Adv Neurol Disord. 2010 Nov;3(6):333-7. doi: 10.1177/1756285610389655.

BACKGROUND: Pramipexole is one of a new generation of dopamine agonists. Recently there have been questions regarding its neuroprotective effects. These effects have been tested against various insults, which have yielded conflicting results.METHODS: In this study, we introduced a...

Cite
Elhak SG, Ghanem AA, Abdelghaffar H, et al. The role of pramipexole in a severe Parkinson's disease model in mice. Ther Adv Neurol Disord. 2010;3(6):333-7doi: 10.1177/1756285610389655.
Elhak, S. G., Ghanem, A. A., Abdelghaffar, H., Eldakroury, S., Eltantawy, D., Eldosouky, S., & Salama, M. (2010). The role of pramipexole in a severe Parkinson's disease model in mice. Therapeutic advances in neurological disorders, 3(6), 333-7. https://doi.org/10.1177/1756285610389655
Elhak, Seham Gad, et al. "The role of pramipexole in a severe Parkinson's disease model in mice." Therapeutic advances in neurological disorders vol. 3,6 (2010): 333-7. doi: https://doi.org/10.1177/1756285610389655
Elhak SG, Ghanem AA, Abdelghaffar H, Eldakroury S, Eltantawy D, Eldosouky S, Salama M. The role of pramipexole in a severe Parkinson's disease model in mice. Ther Adv Neurol Disord. 2010 Nov;3(6):333-7. doi: 10.1177/1756285610389655. PMID: 21179594; PMCID: PMC3002641.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 439 entries